FolioStart free

Medicine · Literature

Research papers on Alzheimer’s disease biomarkers

Recent and highly-cited academic work on alzheimer’s disease biomarkers, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →Or track new alzheimer’s disease biomarkers papers automatically as they publish

  1. Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?

    K. A. Jellinger, Bernd Janetzky, Johannes Attems, et al. · 2008 · Journal of Cellular and Molecular Medicine · 70 citations

    Simple, non-invasive tests for an early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers (plasma/serum, platelets, urine, connective tissue) for the early diagnosis of Alzheimer disease (AD) are available. In disease stages with evident cognitive disturbances, the clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. Diagnostic sensitivity and specificity even in early disease stages are improved by CSF markers, in particular combined tau and amyloid beta peptides (Abeta) and plasma markers (eg, Abeta-42/Abeta-40 r

    Save this paper

  3. Combined Biomarkers for Early Alzheimer Disease Diagnosis

    Barbara Borroni, Enrico Premi, Mónica Di Luca, et al. · 2007 · Current Medicinal Chemistry · 36 citations

    Few public health problems have captured the attention of the biomedical and lay communities alike as has Alzheimer Disease (AD). Several questions remain still open in disease management, as the necessity to delineate disease process from "normal ageing". In the last few years, Mild Cognitive Impairment (MCI) has received significant attention, thus it represents the major risk factor for AD. Not all people diagnosed as having MCI, however, will develop AD, hence there is a need to reliably predict progression. To this aim, different biomarkers have been proposed with the attempt to identify MCI people who already have pre-clinical AD. Neuropsychological assessment, peripheral and CSF bioma

    Save this paper

  4. Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development

    Carmen Peña‐Bautista, Miguel Baquero, Máximo Vento, et al. · 2018 · Current Neuropharmacology · 35 citations

    BACKGROUND: Alzheimer's disease (AD), the most common cause of dementia in adulthood, has great medical, social, and economic impact worldwide. Available treatments result in symptomatic relief, and most of them are indicated from the early stages of the disease. Therefore, there is an increasing body of research developing accurate and early diagnoses, as well as diseasemodifying therapies. OBJECTIVE: Advancing the knowledge of AD physiopathological mechanisms, improving early diagnosis and developing effective treatments from omics-based biomarkers. METHODS: Studies using omics technologies to detect early AD, were reviewed with a particular focus on the metabolites/lipids, micro-RNAs and

    Save this paper

  6. A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease

    Felix Kork, Jan Holthues, Rainer Hellweg, et al. · 2009 · Current Alzheimer Research · 28 citations

    Early diagnosis in patients with Alzheimer's disease (AD) is of great importance since only a sufficient treatment in early stages of this disease helps to keep patients in an autonomous state for as long as possible. Until now, there is no single diagnostic biomarker for AD derived from material routinely obtained. In this study, proton nuclear magnetic resonance (1H-NMR) spectra of the cerebrospinal fluid (CSF) of AD patients were compared with 1H-NMR spectra of the CSF of healthy control subjects using a metabonomic approach. The 1H-NMR spectra of CSF of AD patients showed specific multiplets at 2.15 ppm and 2.45 ppm, which could not be detected in the majority (59.3% and 70.4%, respectiv

    Save this paper

  8. Biomarkers for early onset Alzheimer disease diagnosis

    María Camila Peña, Paula Catalina Pérez, Maria Camila Ramirez, et al. · 2020 · Repositorio Institucional Universidad El Bosque

    La enfermedad de Alzheimer, es una entidad neurodegenerativa que afecta gran parte de la población mundial, las secuelas físicas y mentales son variadas. Su presencia supone unas limitaciones laborales, familiares y económicas. El reto diagnóstico se basa en anticiparse a la aparición de síntomas, es por esto que el advenimiento de biomarcadores se ha convertido en una herramienta para el diagnóstico molecular, monitoreo y pronóstico de la enfermedad en la fase preclínica, dejando atrás las herramientas clínicas y radiológicas. Dentro de los biomarcadores encontrados están: los marcadores ATN: derivados de proteína amiloide (A), los marcadores de Taupatía (T), los marcadores de degeneración

    Save this paper

  9. The study of plasma biomarker for early diagnosis of Alzheimer disease

    Pengpeng Fan, Xu Wang, Li Jun Sun, et al. · 2017 · Zhonghua laonian yixue zazhi

    Objective To extract, detect and validate the BACE1 expression-regulating lncRNA BACE1-AS containing in the plasma of patients with AD in Chinese Han people, so as to provide a research basis for plasma BACE1-AS in AD to be a plasma molecular markers and a new target for treatment. Methods The study included 27 AD patients and 28 normal individuals whose age, sex, education, etc.were matched between AD and control group.Total RNA extraction of plasma was performed using guanidine isothiocyanate-phenol chloroform method.Target gene amplification was executed by RT-PCR Kit.Gel electrophoresis and its imaging analysis were performed on the RT-PCR-amplified products.Target gene amplified product

    Save this paper

  11. Cerebrospinal fluid biomarkers for early diagnosis of Alzheimer disease

    Sun Yingz · 2011 · Zhongguo shenjing jingshen jibing zazhi

    Objective To investigate the cerebrospinal fluid(CSF) levels of tau protein and β-amyloid peptide1-42(Aβ1-42) in the patients with Alzheimer disease(AD) and their diagnosetic value for AD.Methods The subjects were 36 patients with AD and 26 controls,includeing 24 patients with vascular dementia(VD) and 26 normal controls(NC).The CSF levels of tau protein and Aβ1-42 were measured with ELISA.Results The mean CSF levels of tau protein were(336 ± 126) ng/L in AD patients,(183 ± 96) ng/L in VD,and(98 ± 54) ng/L in NC,respectively,and the difference between AD and NC was statistically significant(P 0.05).The mean CSF levels of Aβ1-42 were(341 ± 113)ng/L in AD,(457 ± 132)ng/L in VD,and(502 ± 167) n

    Save this paper

  12. Hippocampus-to-ventricle-ratio (HVR) as a novel biomarker for early diagnosis of Alzheimer disease (AD)

    Xiang Hu · 2024 · KOPS (University of Konstanz)

    As a progressive and irreversible disease, Alzheimer disease (AD) poses a serious health risk, as well as a heavy burden on caregivers, families, and society. Currently, AD cannot be cured, and the limited treatments available can only slow down the deterioration of symptoms. Therefore, diagnosis of AD in the preclinical stage is critical. Earlier diagnosis means a chance to slow down the disease at an earlier stage. However, AD has an insidious onset and can have a latent period of more than 10 years before symptoms appear. During this period, early onset biological markers of AD indexes can assist the diagnosis. Structural imaging studies have demonstrated that the medial temporal lobe (MT

    Save this paper

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →